A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

(2012) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera

(2012) J.-C. Hernandez-Boluda et al.   BLOOD

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

(2012) Junko H Ohyashiki et al.   BMC Medical Genetics

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis

(2012) Giovanni Barosi et al.   PLoS One

Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm

(2011) Elisa Rumi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia

(2011) L. Varricchio et al.   BLOOD

The dominant negative   isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients

(2011) L. Varricchio et al.   BLOOD

BCR-ABL1—Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment

(2011) Erik Vakil et al.   Clinical Lymphoma Myeloma & Leukemia

Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts

(2011) T L Lasho et al.   LEUKEMIA

Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies

(2011) A Harutyunyan et al.   LEUKEMIA

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

(2010) A. V. Jones et al.   BLOOD

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients

(2009) A Pardanani et al.   LEUKEMIA

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

(2009) A Tefferi et al.   LEUKEMIA

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Hypermethylation ofCXCR4Promoter in CD34+Cells from Patients with Primary Myelofibrosis

(2008) Costanza Bogani et al.   STEM CELLS